Division of Allergy, Pulmonary, and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, TN, United States.
Department of Pathology, Microbiology, and Immunology, Vanderbilt University School of Medicine, Nashville, TN, United States.
Front Immunol. 2022 Oct 4;13:1014774. doi: 10.3389/fimmu.2022.1014774. eCollection 2022.
Innate lymphoid cells (ILCs) are a critical element of the innate immune system and are potent producers of pro-inflammatory cytokines. Recently, however, the production of the anti-inflammatory cytokine IL-10 has been observed in all ILC subtypes (ILC1s, ILC2s, and ILC3s) suggesting their ability to adopt a regulatory phenotype that serves to maintain lung and gut homeostasis. Other studies advocate a potential therapeutic role of these IL-10-expressing ILCs in allergic diseases such as asthma, colitis, and pancreatic islet allograft rejection. Herein, we review IL-10 producing ILCs, discussing their development, function, regulation, and immunotherapeutic potential through suppressing harmful inflammatory responses. Furthermore, we address inconsistencies in the literature regarding these regulatory IL-10 producing ILCs, as well as directions for future research.
先天淋巴细胞 (ILCs) 是先天免疫系统的关键组成部分,是促炎细胞因子的有力产生者。然而,最近在所有 ILC 亚型(ILC1、ILC2 和 ILC3)中观察到抗炎细胞因子 IL-10 的产生,表明它们能够采用调节表型,从而维持肺和肠道的稳态。其他研究提倡这些表达 IL-10 的 ILC 在过敏性疾病(如哮喘、结肠炎和胰岛同种异体移植物排斥反应)中具有潜在的治疗作用。在此,我们综述了产生 IL-10 的 ILC,讨论了它们通过抑制有害炎症反应的发育、功能、调节和免疫治疗潜力。此外,我们还解决了关于这些调节性 IL-10 产生 ILC 的文献中的不一致性,以及未来研究的方向。